09:00 - 09:15 Opening & Welcome
09:15 - 10:00 Keynote: Classification and epidemiology of secondary and therapy-related leukemias
- Coleman Lindsley (United States)
10:00 - 10:30 Coffee break
10:30 - 11:45 Session 1: Susceptibility and mechanisms of secondary leukemogenesis
- BM-failure syndromes
Carmelo Gurnari (Italy)
- DDX41 and other susceptibility genes
Marie Sebert (France)
- TP53 and other classifier mutations
Andrew Wei (Australia)
11:45 - 13:00 Oral Abstracts Session 1
- NAVIGATING THE BORDERLAND OF SECONDARY ΑΜL: REFINING THE DIAGNOSTIC QUALIFIERS AND EVALUATING THE IMPACT OF 20% BLAST THRESHOLD
Enrico Attardi (Italy)
- HIGHLY VARIABLE ALTERNATIVE SPLICING PROFILES IN SPLICEOSOME-MUTATED SECONDARY AML REVEALED BY LONG-READ SINGLE-CELL SEQUENCING
Jonas Berger (Germany)
- COMPREHENSIVE MULTI-OMICS EXPLORATION OF MOUSE MODELS REFLECTING RECURRENT MUTATIONS OF HUMAN AML
Paul Jung (Germany)
- CANCER GENE DISCOVERY IN ASXL1-MUTATED AML THROUGH SINGLE-CELL TRANSPOSON AND TRANSCRIPTOME SEQUENCING
Francis Baumgartner (Germany)
- CARTOGRAPHY OF CLINICAL AND MOLECULAR FEATURES OF THERAPY-RELATED MYELOID NEOPLASMS: INSIGHTS FROM THE ITALIAN REGISTRY
Elisa Meddi (Italy)
- SWING BETWEEN TWO LINEAGES. THE EXCEPTIONAL CASE OF PRIMARY MYELOFIBROSIS TRANSFORMATION TO ACUTE LYMPHOBLASTIC LEUKEMIA AND SUBSEQUENT RELAPSE OF ACUTE MYELOID LEUKEMIA
Magdalena Karasek (Poland)
13:00 - 14:00 Lunch break
Breakout Sessions
14:00 - 15:30 Breakout A: Drugs and diseases in th-related AML
- Solid tumors and PARPi
Elisabetta Todisco (Italy)
- Hematologic malignancies (topo-II inhibitors, lenalidomide, autologous transplantation)
Sylvain Garciaz (France)
- Secondary leukemias with recurrent genetic abnormalities
Coleman Lindsley (United States)
14:00 - 15:30 Breakout B
- Quantitative dynamics for transformation of MDS to AML
Verena Korber (United Kingdom)
- AML microenvironment
Dominique Bonnet (United Kingdom)
- Modelling secondary AML using human iduced pluripotent stem cells
Eirini Papapetrou (United States)
15:30 - 15:45 Coffee break
15:45 - 17:00 Session 2: Mechanisms of clonal progression
- CHIP and clinical management
Kirsten Grønbæk (Denmark)
- Clonal trajectories from normal hemopoiesis to clonal hemopoiesis (CH and CCUS) to MDS and MPD and then to AML
Coleman Lindsley (United States)
- Progressive immune remodeling as hemopoiesis changes over time from normal hemopoiesis to sAML
Shahram Kordasti (United Kingdom)
17:00 - 18:00 Satellite Symposium
18:00 - 19:00 Welcome reception & poster walk
Back